Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 85 years old
- People who have never had a prostate biopsy before
- People who have more than one suspicious area visible on their prostate MRI scan
- People where every suspicious area on the MRI meets specific guidelines for biopsy (rated PI-RADS 4 or higher, or PI-RADS 3 with clinical suspicion of prostate cancer)
- People with a PSA (prostate-specific antigen) blood test result below 50 ng/ml
- People whose MRI scan is complete and of sufficiently high quality (scored 3 or above on a standard quality rating scale)
- People whose prostate biopsy was performed within one month of their prostate MRI scan
- People who have complete biopsy results available
- People who have complete medical records and clinical information available
Who may not be able to join:
- People who cannot safely have an MRI scan — for example, those with certain metal implants, claustrophobia (fear of enclosed spaces), epilepsy, high fever, coma, or a risk of cardiac arrest
- People who cannot safely have a prostate biopsy — for example, those with an active infection or fever, a severe bleeding disorder, uncontrolled high blood pressure or diabetes, severe heart failure, or significant haemorrhoid or rectal conditions (confirm with trial site)
- People who have previously received radiotherapy, chemotherapy, hormone therapy, or surgery for prostate cancer
- People who have had a prostate biopsy in the past
- People whose MRI scan shows no suspicious areas, or only a single suspicious area
- People whose MRI suspicious areas are rated below PI-RADS 3 on the standard scoring system
- People whose MRI data is incomplete or of insufficient quality
- People who are unable to cooperate with completing the biopsy procedure
- People, or their family members, who have declined to participate in the study
- People whose clinical or medical information is incomplete
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yi LIU, Peking University First Hospital
Phone: +86 13611035261
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The clinically significant prostate cancer (csPCa) detection rate for TPLBx and CTSBx schemes
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.